Graves眼病与肢端肥大症的眼外肌增大模式比较
回顾性队列研究纳入16例Graves眼病、17例肢端肥大症及18例年龄性别匹配的垂体大腺瘤对照,用CT测量眼外肌最大直径与横截面积。Graves眼病组下直肌、内直肌、上直肌显著大于对照,肢端肥大症组四条直肌均大于对照,两组间无显著差异。
要点
- Graves眼病组下直肌、内直肌、上直肌最大直径显著大于对照,外直肌无显著差异。
- 肢端肥大症组四条直肌最大直径均显著大于对照。
- Graves眼病组与肢端肥大症组各直肌最大直径均无显著差异。
核心结论
- Graves眼病组与肢端肥大症组下直肌、内直肌、上直肌均较对照增大,Graves眼病组眼外肌大小未显著大于肢端肥大症组。
- Graves眼病组下直肌、内直肌、上直肌受累程度相近,未遵循既往描述的Graves眼病增大模式。
研究设计与样本
- 回顾性队列研究,纳入2015年1月1日至2020年7月1日在加拿大安大略省伦敦市圣约瑟夫医疗中心就诊的新诊断肢端肥大症或Graves眼病患者,并有足够眼眶CT成像。
- 纳入16例Graves眼病患者、17例肢端肥大症患者及18例年龄性别匹配的无甲状腺或生长激素异常的垂体大腺瘤对照。
- 眼眶CT由单一神经放射科医生分析,测量每块眼外肌的最大直径和横截面积,采用方差分析分别分析各直肌受累的相对可能性。
主要发现
- 各组年龄(均值±标准差)分别为Graves眼病组55.6±18.0岁、肢端肥大症组50.2±15.7岁、对照组49.3±14.0岁。
- 眼外肌最大直径(均值±标准差):下直肌Graves眼病组4.77±1.53 mm、肢端肥大症组4.66±0.61 mm、对照组3.68±0.61 mm;内直肌分别为5.35±2.23 mm、4.84±0.81 mm、3.65±0.42 mm;上直肌分别为4.94±1.84 mm、4.88±0.91 mm、3.68±0.61 mm;外直肌分别为3.91±1.59 mm、4.55±0.60 mm、3.20±0.43 mm。
- Graves眼病组与对照比较:下直肌p=0.020、上直肌p=0.004、内直肌p<0.001显著增大,外直肌p=0.166无显著差异。
- 肢端肥大症组与对照比较:下直肌p=0.039、上直肌p=0.006、内直肌p=0.006、外直肌p=0.001均显著增大。
- Graves眼病组与肢端肥大症组比较:下直肌p=0.959、上直肌p=0.987、内直肌p=0.408、外直肌p=0.250,均无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: Extraocular muscle (EOM) enlargement occurs in both acromegaly and Graves' disease, but the degree and pattern of enlargement have not been directly compared in these patient groups. This study investigated whether acromegaly and Graves' orbitopathy (GO) are associated with different patterns of EOM enlargement at the time of diagnosis. Study Design: Retrospective cohort. Methods: All new patients with a diagnosis of acromegaly or GO who presented to St Joseph's Health Care in London, Ontario, between January 1, 2015, and July 1, 2020, and who underwent computed tomography (CT) scanning with adequate orbital imaging were considered for inclusion. We included age- and sex-matched control patients with pituitary macroadenomas without thyroid or growth hormone abnormalities. Orbital CT scans were analyzed by a single neuroradiologist, who measured the maximum diameter and cross-sectional area of each EOM. The relative likelihood of involvement of each rectus EOM was analyzed separately using an analysis of variance test. Results: We included 16 patients with GO, 17 with acromegaly, and 18 controls. Ages (mean ± standard deviation) of groups were 55.6 ± 18.0, 50.2 ± 15.7, and 49.3 ± 14.0 years. The mean maximum diameter of EOMs in GO, acromegaly, and controls was inferior rectus (IR) = 4.77 ± 1.53, 4.66 ± 0.61, and 3.68 ± 0.61 mm; medial rectus (MR) = 5.35 ± 2.23, 4.84 ± 0.81, and 3.65 ± 0.42 mm; superior rectus (SR) = 4.94 ± 1.84, 4.88 ± 0.91, and 3.68 ± 0.61 mm; and lateral rectus (LR) = 3.91 ± 1.59, 4.55 ± 0.60, and 3.20 ± 0.43 mm. The IR, MR, and SR muscles were significantly larger in the GO group compared with controls (IR, p = 0.020; SR, p = 0.004; MR, p < 0.001; and LR, p = 0.166), and all four EOMs were larger in acromegaly compared with controls (IR, p = 0.039; SR, p = 0.006; MR, p = 0.006; and LR, p = 0.001). There was no significant difference between the GO and acromegaly groups (IR, p = 0.959; SR, p = 0.987; MR, p = 0.408; and LR, p = 0.250). Conclusions: GO and acromegaly groups demonstrated the enlargement of the IR, MR, and SR muscles when compared with controls. The GO group did not show significantly larger EOM sizes compared with the acromegaly group. In the GO group, the IR, MR, and SR were similarly affected and did not follow previously described patterns of enlargement in GO.
引用
- Zajner C, Patil N, McInnis R, et al. Patterns of Extraocular Muscle Enlargement in Graves' Orbitopathy and Acromegaly. Thyroid. 2024. PMID: 39705079. doi:10.1089/thy.2024.0438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。